Detalhe da pesquisa
1.
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Blood
; 139(9): 1289-1301, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521108
2.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
N Engl J Med
; 373(11): 1040-7, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352815
3.
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
Cancer Res Commun
; 3(5): 821-829, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37377890
4.
PSMA-targeting TGFß-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Nat Med
; 28(4): 724-734, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314843
5.
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Blood Adv
; 3(13): 2022-2034, 2019 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31289029
6.
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
J Clin Invest
; 129(6): 2210-2221, 2019 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30896447
7.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
JCI Insight
; 3(8)2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669947
8.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
JCI Insight
; 4(4)2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830874